文献速递妇科产科

腹腔热灌注化疗在新诊断与复发卵巢癌中的作用:随机试验的时间事件荟萃分析

The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials.
PubMed 文献 · Gynecol Oncol · 2026-03-14

该荟萃分析纳入7项随机对照试验共1300例患者,利用重建的时间事件数据评估腹腔热灌注化疗(HIPEC)在卵巢癌中的疗效。在新诊断卵巢癌中间期减瘤术联合HIPEC显著改善无进展生存(HR=0.65)和总生存(HR=0.68),而复发场景未见显著获益。≥3级不良事件发生率45.7%对36.4%,无统计学差异。

要点

  • 新诊断卵巢癌中间期减瘤术联合HIPEC显著改善PFS和OS。
  • 复发卵巢癌中HIPEC未见显著生存获益,价值尚不明确。
  • 90分钟HIPEC方案似乎效果最明显,严重毒性未显著增加。

核心结论

  • 新诊断卵巢癌中间期减瘤术联合HIPEC可显著改善PFS和OS,尤其90分钟灌注方案,且未明显增加严重毒性。
  • 复发卵巢癌中HIPEC的生存获益不显著,其价值仍需进一步研究。

研究设计与样本

  • 系统检索PubMed、Scopus、Web of Science、CENTRAL和ClinicalTrials.gov(截至2025年6月)的随机对照试验。
  • 纳入7项RCT共1300例患者,比较减瘤术联合或不联合HIPEC,重建Kaplan-Meier曲线时间事件数据进行荟萃分析。

主要发现

  • 新诊断卵巢癌中间期减瘤术后HIPEC组PFS显著改善(HR=0.65,95%CI 0.52-0.82,p<0.001)。
  • 新诊断卵巢癌中间期减瘤术后HIPEC组OS显著改善(HR=0.68,95%CI 0.54-0.86,p=0.001)。
  • 复发卵巢癌中HIPEC组OS无显著获益(HR=0.85,95%CI 0.69-1.03,p=0.10),PFS亦无显著获益(HR=0.95,95%CI 0.81-1.12,p=0.52)。
  • 复发卵巢癌PFS的RMST在HIPEC组为2.25年(95%CI 1.95-2.55),对照组2.27年(95%CI 1.94-2.60),ΔRMST=-0.02年(95%CI -0.46至0.43,p=0.94)。
  • ≥3级不良事件在HIPEC组为45.7%,对照组36.4%(RR=1.17,95%CI 0.87-1.58,p=0.29),常见为电解质紊乱和肾功能异常,通常轻微可逆。

关键数值与推荐

  • 新诊断卵巢癌新辅助化疗后中间期减瘤术联合HIPEC:PFS HR=0.65(95%CI 0.52-0.82,p<0.001),OS HR=0.68(95%CI 0.54-0.86,p=0.001)。
  • 复发卵巢癌:OS HR=0.85(95%CI 0.69-1.03,p=0.10),PFS HR=0.95(95%CI 0.81-1.12,p=0.52)。
  • 亚组分析提示90分钟HIPEC方案效果最明显。

临床怎么用

  • 对新诊断卵巢癌接受新辅助化疗后中间期减瘤术的患者,可考虑联合HIPEC以改善生存。
  • 复发卵巢癌患者不推荐常规应用HIPEC,需个体化评估并优先考虑临床试验。
  • 实施HIPEC时需关注电解质紊乱和肾功能等毒性,但严重不良事件风险未显著增加。

局限性

  • 基于重建Kaplan-Meier曲线的时间事件数据,可能存在估算偏差。
  • 纳入研究数量有限(7项RCT),亚组分析结果需谨慎解读。
  • 复发场景中HIPEC的疗效证据不足,结论受异质性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer remains debated, with inconsistent results across clinical settings. This meta-analysis used reconstructed time-to-event data from randomized trials to provide a time-sensitive evaluation of HIPEC's therapeutic impact. METHODS: A systematic search of PubMed, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov (through June 2025) identified randomized controlled trials (RCTs) comparing cytoreductive surgery (CRS) with or without HIPEC in newly diagnosed or recurrent ovarian cancer. Time-to-event data were reconstructed from published Kaplan-Meier curves to generate pooled analyses for progression-free survival (PFS) and overall survival (OS), supplemented by restricted mean survival time (RMST) estimates. Subgroup analyses were performed by disease setting and HIPEC duration, and safety outcomes were synthesized using a random-effects model. RESULTS: Seven RCTs comprising 1300 patients (CRS alone, n = 653; CRS + HIPEC, n = 647) met the inclusion criteria. In newly diagnosed ovarian cancer treated with interval CRS after neoadjuvant chemotherapy, HIPEC conferred a significant survival advantage, improving both PFS (HR = 0.65, 95% CI 0.52-0.82, p < 0.001) and OS (HR = 0.68, 95% CI 0.54-0.86, p = 0.001). In contrast, no statistically significant benefit was detected in the recurrent setting (OS: HR = 0.85, 95% CI 0.69-1.03, p = 0.10; PFS: HR = 0.95, 95% CI 0.81-1.12, p = 0.52). For recurrent disease, the RMST for PFS was 2.25 years (95% CI 1.95-2.55) with HIPEC versus 2.27 years (95% CI 1.94-2.60) with CRS alone, yielding a ΔRMST of -0.02 years (95% CI -0.46 to 0.43, p = 0.94). Subgroup analyses suggested the most pronounced effect with 90-min HIPEC protocols. Grade ≥ 3 adverse events occurred in 45.7% of patients receiving HIPEC compared with 36.4% in the control arm (RR = 1.17, 95% CI 0.87-1.58, p = 0.29). The most frequent toxicities were electrolyte disturbances and renal dysfunction, both typically mild and reversible. CONCLUSIONS: HIPEC significantly improves PFS and OS when integrated with interval CRS for newly diagnosed ovarian cancer, particularly with a 90-min perfusion, without a meaningful rise in severe toxicity. Its value in recurrent disease remains uncertain and requires further investigations. PROTOCOL REGISTRATION: This meta-analysis was prospectively registered in PROSPERO (registration number: CRD420251152447).

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Altayf A, Nelson G, Chiva LM, et al. The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials. Gynecol Oncol. 2026. PMID: 41831249. doi:10.1016/j.ygyno.2026.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。